ThromboGenics Struggles to Find Patients for Phase II Eye Disease Trial Post author:Sam Post published:December 7, 2017 Post category:BioPharma Resources redirected to progress new drug candidates to clinic in H1 2018. Source: BioSpace You Might Also Like Teva's Shrinking U.S. Footprint February 22, 2018 Teva Board Members Take 50% Pay Cut January 10, 2018 ORIC Pharmaceuticals Snags $50 Million to Advance Lead Asset for Treatment-Resistant Cancers February 20, 2018
ORIC Pharmaceuticals Snags $50 Million to Advance Lead Asset for Treatment-Resistant Cancers February 20, 2018
